Office of the Director, National Institutes of Health; Notice of Meeting, 48320 [2018-20665]
Download as PDF
48320
Federal Register / Vol. 83, No. 185 / Monday, September 24, 2018 / Notices
NIAID inventors have identified a multivalent tolerogen (MMPt), which can
specifically elicit RICD of the activated,
disease causing autoimmune T cells
without compromising the general T
cell-dependent immunity in the host.
Animal studies have demonstrated that
MMPt exerts robust therapeutic effects
on both monophasic as well as
relapsing-remitting type of the disease,
indicating its medical applicability for
treating MS patients with active disease.
NIAID is seeking partners to develop
this multi-valent peptide to improve its
efficacy for use in clinical trials.
This technology is available for
licensing for commercial development
in accordance with 35 U.S.C. 209 and 37
CFR part 404, as well as for further
development and evaluation under a
research collaboration.
Potential Commercial Applications:
• Therapeutics
Competitive Advantages:
• Tolerogen induced elimination of
activated autoimmune T cells will
overcome the fatal side effects of
current therapies
• Treatment of all types of MS patients
Development Stage:
amozie on DSK3GDR082PROD with NOTICES1
• Preclinical (In vitro and in vivo
animal studies)
Inventors: Dr. Michael J. Lenardo
(NIAID), Dr. Lixin Zheng (NIAID), Dr.
Jian Li (NIAID), Dr. Jae Lee (NIAID), and
Dr. Wei Lu (NIAID).
Intellectual Property: HHS Reference
No. E–064–2015, U.S. Provisional Patent
Application Numbers: 62/130,285 filed
March 9, 2015 and 62/219,851 filed
September 17, 2015, and US PCT
application PCT/US2016/021571 filed
on March 9, 2016. Entered National
Stage filing in US, EU, Canada, and
Australia.
Licensing Contact: Yogikala Prabhu,
Ph.D., 301–761–7789; prabhuyo@
niaid.nih.gov.
Collaborative Research Opportunity:
The National Institute of Allergy and
Infectious Diseases is seeking statements
of capability or interest from parties
interested in collaborative research to
further develop, evaluate or
commercialize the MMPt peptide to
improve its efficacy for use in clinical
trials.
For collaboration opportunities,
please contact Yogikala Prabhu, Ph.D.,
301–761–7789; prabhuyo@
niaid.nih.gov.
VerDate Sep<11>2014
17:40 Sep 21, 2018
Jkt 244001
Dated: September 18, 2018.
Suzanne M. Frisbie,
Deputy Director, Technology Transfer and
Intellectual Property Office, National Institute
of Allergy and Infectious Diseases.
[FR Doc. 2018–20664 Filed 9–21–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Office of the Director, National
Institutes of Health; Notice of Meeting
Pursuant to section 10(a) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the Advisory Committee on
Research on Women’s Health.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting. The meeting
will also be videocast and can be
accessed from the NIH Videocasting and
Podcasting website (https://
videocast.nih.gov/).
Name of Committee: Advisory Committee
on Research on Women’s Health.
Date: October 23, 2018.
Time: 9:00 a.m. to 4:00 p.m.
Agenda: Opening Remarks, Director’s
Report, Scientific Presentations, ORWH
SCORE Program Update, and Strategic Plan
Launch.
Place: National Institutes of Health,
Building 31, 6th Floor, Conference Room 10,
31 Center Drive, Bethesda, MD 20892.
Contact Person: Elizabeth Spencer, R.N.,
Deputy Director, Office of Research on
Women’s Health, Executive Secretary,
ACRWH, National Institutes of Health, 6707
Democracy Blvd., Room 7W444, Bethesda,
MD 20817, 301–402–1770,
elizabeth.spencer@nih.gov.
Any member of the public interested in
presenting oral comments to the committee
may notify the Contact Person listed on this
notice at least 10 days in advance of the
meeting. Interested individuals and
representatives of organizations may submit
a letter of intent, a brief description of the
organization represented, and a short
description of the oral presentation. Only one
representative of an organization may be
allowed to present oral comments and if
accepted by the committee, presentations
may be limited to five minutes. Both printed
and electronic copies are requested for the
record. In addition, any interested person
may file written comments with the
committee by forwarding their statement to
the Contact Person listed on this notice. The
statement should include the name, address,
telephone number and when applicable, the
PO 00000
Frm 00047
Fmt 4703
Sfmt 4703
business or professional affiliation of the
interested person.
In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors will be asked to show one
form of identification (for example, a
government-issued photo ID, driver’s license,
or passport) and to state the purpose of their
visit.
Information is also available on the
Institute’s/Center’s home page: https://
orwh.od.nih.gov/, where an agenda and any
additional information for the meeting will
be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.14, Intramural Research
Training Award; 93.22, Clinical Research
Loan Repayment Program for Individuals
from Disadvantaged Backgrounds; 93.232,
Loan Repayment Program for Research
Generally; 93.39, Academic Research
Enhancement Award; 93.936, NIH Acquired
Immunodeficiency Syndrome Research Loan
Repayment Program; 93.187, Undergraduate
Scholarship Program for Individuals from
Disadvantaged Backgrounds, National
Institutes of Health, HHS)
Dated: September 18, 2018.
Ronald J. Livingston, Jr.,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–20665 Filed 9–21–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Office of the Director, National
Institutes of Health; Notice of Meeting
Pursuant to section 10(a) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the NIH Clinical Center
Research Hospital Board.
The meeting will be open to the
public, with attendance limited to space
available. Individuals who plan to
attend and need special assistance, such
as sign language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
Name of Committee: NIH Clinical Center
Research Hospital Board.
Date: October 19, 2018.
Time: 9:00 a.m. to 3:25 p.m.
Agenda: Discussion of Patient Safety.
Place: National Institutes of Health,
Building 31, 6th Floor, Room: 6C6, 31 Center
Drive, Bethesda, MD 20892.
Contact Person: Gretchen Wood, Staff
Assistant, Office of the Director, National
Institutes of Health, One Center Drive,
Building 1, Bethesda, MD 20892, 301–496–
4272, woodgs@nih.gov.
E:\FR\FM\24SEN1.SGM
24SEN1
Agencies
[Federal Register Volume 83, Number 185 (Monday, September 24, 2018)]
[Notices]
[Page 48320]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-20665]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Office of the Director, National Institutes of Health; Notice of
Meeting
Pursuant to section 10(a) of the Federal Advisory Committee Act, as
amended, notice is hereby given of a meeting of the Advisory Committee
on Research on Women's Health.
The meeting will be open to the public as indicated below, with
attendance limited to space available. Individuals who plan to attend
and need special assistance, such as sign language interpretation or
other reasonable accommodations, should notify the Contact Person
listed below in advance of the meeting. The meeting will also be
videocast and can be accessed from the NIH Videocasting and Podcasting
website (https://videocast.nih.gov/).
Name of Committee: Advisory Committee on Research on Women's
Health.
Date: October 23, 2018.
Time: 9:00 a.m. to 4:00 p.m.
Agenda: Opening Remarks, Director's Report, Scientific
Presentations, ORWH SCORE Program Update, and Strategic Plan Launch.
Place: National Institutes of Health, Building 31, 6th Floor,
Conference Room 10, 31 Center Drive, Bethesda, MD 20892.
Contact Person: Elizabeth Spencer, R.N., Deputy Director, Office
of Research on Women's Health, Executive Secretary, ACRWH, National
Institutes of Health, 6707 Democracy Blvd., Room 7W444, Bethesda, MD
20817, 301-402-1770, [email protected].
Any member of the public interested in presenting oral comments
to the committee may notify the Contact Person listed on this notice
at least 10 days in advance of the meeting. Interested individuals
and representatives of organizations may submit a letter of intent,
a brief description of the organization represented, and a short
description of the oral presentation. Only one representative of an
organization may be allowed to present oral comments and if accepted
by the committee, presentations may be limited to five minutes. Both
printed and electronic copies are requested for the record. In
addition, any interested person may file written comments with the
committee by forwarding their statement to the Contact Person listed
on this notice. The statement should include the name, address,
telephone number and when applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has instituted stringent
procedures for entrance onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles will be inspected
before being allowed on campus. Visitors will be asked to show one
form of identification (for example, a government-issued photo ID,
driver's license, or passport) and to state the purpose of their
visit.
Information is also available on the Institute's/Center's home
page: https://orwh.od.nih.gov/, where an agenda and any additional
information for the meeting will be posted when available.
(Catalogue of Federal Domestic Assistance Program Nos. 93.14,
Intramural Research Training Award; 93.22, Clinical Research Loan
Repayment Program for Individuals from Disadvantaged Backgrounds;
93.232, Loan Repayment Program for Research Generally; 93.39,
Academic Research Enhancement Award; 93.936, NIH Acquired
Immunodeficiency Syndrome Research Loan Repayment Program; 93.187,
Undergraduate Scholarship Program for Individuals from Disadvantaged
Backgrounds, National Institutes of Health, HHS)
Dated: September 18, 2018.
Ronald J. Livingston, Jr.,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2018-20665 Filed 9-21-18; 8:45 am]
BILLING CODE 4140-01-P